Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for stem cell transplant patients: drug combo targets GVHD

NCT ID NCT07285889

Recruiting now Disease control Sponsor: First Affiliated Hospital of Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jan 10, 2026 · Last updated May 18, 2026 · Updated 21 times

Summary

This study tests a new drug called gecacitinib (jaktinib) combined with standard steroids as a first treatment for acute graft-versus-host disease (GVHD) in people who had a stem cell transplant. GVHD is a serious condition where donor cells attack the patient's body. The trial will include 35 adults and aims to find the best dose and check safety and early response. Participants must have started steroids no more than 2 days before joining.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE-GRAFT-VERSUS-HOST DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital, Zhejiang University School of Medicine.

    RECRUITING

    Hangzhou, Zhejiang, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.

ACUTE-GRAFT-VERSUS-HOST DISEASE